New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:49 EDTXON, OGENOragenics advancing towards identification of lead antibiotic clinical candidate
Oragenics (OGEN) announced that through its Exclusive Channel Collaboration with Intrexon Corporation (XON), it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 antibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon. Dr. John N. Bonfiglio, CEO of Oragenics, remarked, "The compounds we have selected for final evaluation align with our goal of identifying the first lead compound this year. We plan on meeting with the FDA later this year to discuss the IND enabling activities necessary to submit an IND application by mid-2015. Intrexon’s synthetic biology expertise in collaboration with our scientists has enabled generation of a large library of new potential MU1140 analogs with chemical and biological properties that differentiate from native MU1140. We remain very optimistic that these new lantibiotics will become useful in the fight against certain drug-resistant bacteria.”
News For OGEN;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2014
17:15 EDTXONIntrexon reports Q3 EPS (53c), consensus (16c)
Subscribe for More Information
15:18 EDTXONNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use